GB791644A - Barbiturate pharmaceutical preparations - Google Patents
Barbiturate pharmaceutical preparationsInfo
- Publication number
- GB791644A GB791644A GB11235/56A GB1123556A GB791644A GB 791644 A GB791644 A GB 791644A GB 11235/56 A GB11235/56 A GB 11235/56A GB 1123556 A GB1123556 A GB 1123556A GB 791644 A GB791644 A GB 791644A
- Authority
- GB
- United Kingdom
- Prior art keywords
- barbiturate
- glutarimide
- sodium
- phenobarbitone
- methyl ethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 229940125717 barbiturate Drugs 0.000 title abstract 8
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 title abstract 6
- 239000000825 pharmaceutical preparation Substances 0.000 title abstract 2
- 229960002695 phenobarbital Drugs 0.000 abstract 3
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 abstract 3
- 238000002360 preparation method Methods 0.000 abstract 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 abstract 2
- VIROVYVQCGLCII-UHFFFAOYSA-N amobarbital Chemical compound CC(C)CCC1(CC)C(=O)NC(=O)NC1=O VIROVYVQCGLCII-UHFFFAOYSA-N 0.000 abstract 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 abstract 2
- CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 abstract 2
- KNCYXPMJDCCGSJ-UHFFFAOYSA-N piperidine-2,6-dione Chemical compound O=C1CCCC(=O)N1 KNCYXPMJDCCGSJ-UHFFFAOYSA-N 0.000 abstract 2
- 230000036578 sleeping time Effects 0.000 abstract 2
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 abstract 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 abstract 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 abstract 1
- 229930003347 Atropine Natural products 0.000 abstract 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 abstract 1
- 206010010071 Coma Diseases 0.000 abstract 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 abstract 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 229960001138 acetylsalicylic acid Drugs 0.000 abstract 1
- 229960001301 amobarbital Drugs 0.000 abstract 1
- 229940025084 amphetamine Drugs 0.000 abstract 1
- 229940035676 analgesics Drugs 0.000 abstract 1
- 239000000730 antalgic agent Substances 0.000 abstract 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 abstract 1
- 229940125681 anticonvulsant agent Drugs 0.000 abstract 1
- 239000001961 anticonvulsive agent Substances 0.000 abstract 1
- -1 atropine Chemical compound 0.000 abstract 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 abstract 1
- 229960000396 atropine Drugs 0.000 abstract 1
- 230000036772 blood pressure Effects 0.000 abstract 1
- 229960003874 butobarbital Drugs 0.000 abstract 1
- STDBAQMTJLUMFW-UHFFFAOYSA-N butobarbital Chemical compound CCCCC1(CC)C(=O)NC(=O)NC1=O STDBAQMTJLUMFW-UHFFFAOYSA-N 0.000 abstract 1
- 229960001948 caffeine Drugs 0.000 abstract 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 abstract 1
- 239000000812 cholinergic antagonist Substances 0.000 abstract 1
- 229960004126 codeine Drugs 0.000 abstract 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 abstract 1
- 230000000994 depressogenic effect Effects 0.000 abstract 1
- 229960002179 ephedrine Drugs 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 150000001469 hydantoins Chemical class 0.000 abstract 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 abstract 1
- 239000003326 hypnotic agent Substances 0.000 abstract 1
- 230000000147 hypnotic effect Effects 0.000 abstract 1
- 230000002045 lasting effect Effects 0.000 abstract 1
- SQYNKIJPMDEDEG-UHFFFAOYSA-N paraldehyde Chemical compound CC1OC(C)OC(C)O1 SQYNKIJPMDEDEG-UHFFFAOYSA-N 0.000 abstract 1
- 229960003868 paraldehyde Drugs 0.000 abstract 1
- 229960001412 pentobarbital Drugs 0.000 abstract 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 abstract 1
- 229960003893 phenacetin Drugs 0.000 abstract 1
- 229940125723 sedative agent Drugs 0.000 abstract 1
- 239000000932 sedative agent Substances 0.000 abstract 1
- SQMCFUSVGSBKFK-UHFFFAOYSA-M sodium;5-(cyclohexen-1-yl)-1,5-dimethylpyrimidin-3-ide-2,4,6-trione Chemical compound [Na+].O=C1N(C)C(=O)[N-]C(=O)C1(C)C1=CCCCC1 SQMCFUSVGSBKFK-UHFFFAOYSA-M 0.000 abstract 1
- QGMRQYFBGABWDR-UHFFFAOYSA-N sodium;5-ethyl-5-pentan-2-yl-1,3-diazinane-2,4,6-trione Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)NC1=O QGMRQYFBGABWDR-UHFFFAOYSA-N 0.000 abstract 1
- AXXJTNXVUHVOJW-UHFFFAOYSA-M sodium;5-pentan-2-yl-5-prop-2-enylpyrimidin-3-ide-2,4,6-trione Chemical compound [Na+].CCCC(C)C1(CC=C)C(=O)NC(=O)[N-]C1=O AXXJTNXVUHVOJW-UHFFFAOYSA-M 0.000 abstract 1
- 239000000021 stimulant Substances 0.000 abstract 1
- 238000011287 therapeutic dose Methods 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- HFFLGKNGCAIQMO-UHFFFAOYSA-N trichloroacetaldehyde Chemical compound ClC(Cl)(Cl)C=O HFFLGKNGCAIQMO-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A pharmaceutical preparation, which may take the form of tablets, capsules or elixirs, comprises a medicinal barbiturate and a proportion of b ,b -methyl ethyl glutarimide insufficient to interfere with a therapeutic dose of barbiturate but sufficient to overcome the toxic effects of overdose. The glutarimide is present in the proportion of 5 to 30 per cent by weight of the barbiturate. Examples of suitable barbiturates are phenobarbitone, amylobarbitone, butobarbitone, pentobarbitone sodium, quinalbarbitone sodium or hexobarbitone sodium, and when a long acting barbiturate such as phenobarbitone is used the preparation may embody an agent that will delay the release of the b ,b -methyl ethyl glutarimide in the gastro-intestinal tract, such an agent may be cellulose acetate phthalate. Clinical trials with animals and humans using barbiturate dosages of from 15 to 100 mgm. show no significant difference in the sleeping times whether b ,b -methyl ethyl glutarimide is present or not, but in trials using dosages of barbiturates that normally produce a coma lasting 30 to 36 hours, e.g. 2 gms. of phenobarbitone or 1.3 gms. of pentobarbitone, the sleeping time was reduced to about 6 to 8 hours and vital body functions such as blood pressure were not seriously depressed, if 15 to 20 per cent by weight of the glutarimide was contained in the preparations administered. The preparations may also contain stimulants such as caffeine or amphetamine, mild sedatives such as sodium bromide, hypnotics such as chloral or paraldehyde, analgesics such as aspirin, phenacetin or codeine, antiasthamatics such as ephedrine, anticholinergics such as atropine, or anticonvulsants such as hydantoins.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU791644X | 1955-04-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB791644A true GB791644A (en) | 1958-03-05 |
Family
ID=3758886
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB11235/56A Expired GB791644A (en) | 1955-04-20 | 1956-04-12 | Barbiturate pharmaceutical preparations |
Country Status (1)
| Country | Link |
|---|---|
| GB (1) | GB791644A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3966940A (en) * | 1973-11-09 | 1976-06-29 | Bristol-Myers Company | Analgetic compositions |
| US6458384B2 (en) | 2000-02-23 | 2002-10-01 | Impetus Ag | Pharmaceutical with predetermined activity profile |
| US7682633B2 (en) | 2006-06-19 | 2010-03-23 | Alpharma Pharmaceuticals, Llc | Pharmaceutical composition |
| US8623418B2 (en) | 2007-12-17 | 2014-01-07 | Alpharma Pharmaceuticals Llc | Pharmaceutical composition |
| US8685443B2 (en) | 2002-09-20 | 2014-04-01 | Alpharma Pharmaceuticals Llc | Sequestering subunit and related compositions and methods |
-
1956
- 1956-04-12 GB GB11235/56A patent/GB791644A/en not_active Expired
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3966940A (en) * | 1973-11-09 | 1976-06-29 | Bristol-Myers Company | Analgetic compositions |
| US6458384B2 (en) | 2000-02-23 | 2002-10-01 | Impetus Ag | Pharmaceutical with predetermined activity profile |
| US8685443B2 (en) | 2002-09-20 | 2014-04-01 | Alpharma Pharmaceuticals Llc | Sequestering subunit and related compositions and methods |
| US8685444B2 (en) | 2002-09-20 | 2014-04-01 | Alpharma Pharmaceuticals Llc | Sequestering subunit and related compositions and methods |
| US7682633B2 (en) | 2006-06-19 | 2010-03-23 | Alpharma Pharmaceuticals, Llc | Pharmaceutical composition |
| US7682634B2 (en) | 2006-06-19 | 2010-03-23 | Alpharma Pharmaceuticals, Llc | Pharmaceutical compositions |
| US8158156B2 (en) | 2006-06-19 | 2012-04-17 | Alpharma Pharmaceuticals, Llc | Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist |
| US8846104B2 (en) | 2006-06-19 | 2014-09-30 | Alpharma Pharmaceuticals Llc | Pharmaceutical compositions for the deterrence and/or prevention of abuse |
| US8877247B2 (en) | 2006-06-19 | 2014-11-04 | Alpharma Pharmaceuticals Llc | Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist |
| US8623418B2 (en) | 2007-12-17 | 2014-01-07 | Alpharma Pharmaceuticals Llc | Pharmaceutical composition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS57212114A (en) | Capsule containing allergen activator and preparation therefor | |
| KR850700109A (en) | Antidiuretic DDAVP and its preparation method | |
| NO865195L (en) | PROCEDURE FOR THE MANUFACTURE OF A RETARD PREPARATION OF IBUPROFEN. | |
| US4049803A (en) | Augmentation of blood levels of aspirin | |
| GB791644A (en) | Barbiturate pharmaceutical preparations | |
| US2853418A (en) | Hypnotic composition comprising a barbiturate and beta, beta-methyl ethyl glutarimide | |
| US3197370A (en) | Pyrilamine tannate compositions | |
| GB808269A (en) | Barbiturate pharmaceutical preparations | |
| GB1302266A (en) | ||
| US4120958A (en) | Novel 2-acetoxybenzoic acid-nicotinamide complexes | |
| GB785262A (en) | Improvements in or relating to hypotensive and sedative preparations | |
| GB950162A (en) | Medicines for the treatment of hepatic disorders | |
| US2726984A (en) | Composition for combatting amoebiasis comprising 1:2-bis(4'-arsono-phenylamino)-ethane | |
| GB1110397A (en) | Ephedrine composition | |
| GB1292496A (en) | Dosage units of contraceptive preparations for human use | |
| JP2000229853A (en) | Menstrual pain improving composition | |
| KR830008678A (en) | Analgesic composition | |
| GB1300486A (en) | Compositions for the treatment of respiratory ailments in man | |
| GB1138154A (en) | Improvements in and relating to safeguarding composition containing physiologically active ingredient | |
| JPS57179118A (en) | Antitumor agent | |
| GB876320A (en) | Pharmaceutical compositions containing d-3:5-diiodothyronine | |
| JPS6360926A (en) | Cold remedy | |
| GB1454872A (en) | Anticonvulsant | |
| Tallarida | Phenaphen®/Codeine (Robins) Acetaminophen: Codeine phosphate | |
| GB993601A (en) | Antiviral compositions comprising adenine derivatives |